Neuphoria Therapeutics

NEUP

2.7600.72% ( -0.020 )

Closed: Nov 9, 16:00:00 (EDT)

Current ValuationThe current P/E ratio is -1.11, above the reasonable range, cheaper than 9.2% of the time in the past 1 years, and the industry ranks 226/607, the industry Median -1.88.

-1.11xP/E

Stock price$2.76Earnings per share$-2.49

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.

013263952

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.

0x30x60x90x120x150x

P/E ratio
Name/Symbol
GILDUSGilead Sciences	-54.38x	162.83%	$210.01B
MRNAUSModerna	-38.51x	4.47%	$107.39B
CSLLYUSCSL Limited	-26.11x	--	$67.34B
NTRAUSNatera	-282.05x	0.90%	$46.46B
RVMDUSRevolution Medicines	-22.93x	40.80%	$42.90B
ROIVUSRoivant Sciences	-110.33x	146.69%	$29.38B
INSMUSInsmed	-42.06x	74.47%	$25.47B
BNTXUSBioNTech SE	-12.82x	25.93%	$21.70B
BBIOUSBridgebio Pharma	-25.64x	30.83%	$15.18B
SMMTUSSummit Therapeutics	-17.09x	22.09%	$14.23B
KYMRUSKymera Therapeutics	-33.04x	8.74%	$11.55B
BMRNUSBioMarin Pharma	-579.41x	61.50%	$11.08B
PCVXUSVaxcyte	-9.31x	44.27%	$10.69B
SYREUSSpyre Therapeutics	-46.21x	59.93%	$10.35B
MDGLUSMadrigal Pharma	-64.67x	87.15%	$10.05B
PRAXUSPraxis Precision Medicines	-27.41x	4.01%	$9.30B
TWSTUSTwist Bioscience	-65.17x	28.63%	$8.91B
RYTMUSRhythm Pharma	-39.84x	51.65%	$7.90B
ALKSUSAlkermes	-22,104.19x	133.59%	$7.76B
CYTKUSCytokinetics	-9.87x	8.47%	$7.68B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.